Y-mAbs Therapeutics, Inc. (YMAB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.58 |
| Open | 5.61 |
| Bid | 5.40 x 800 |
| Ask | 8.68 x 800 |
| Day's Range | 5.36 - 5.82 |
| 52 Week Range | 2.70 - 15.89 |
| Volume | |
| Avg. Volume | 185,538 |
| Market Cap | 237.73M |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for YMAB
Related Research
- Y-mAbs Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 05/18/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
GlobeNewswireY-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 55th Congress of the International Society of Pediatric Oncology ("SIOP") to be held October 11-14, 2023 in Ottawa, Canada. The abstracts include the following
- GlobeNewswire
Y-mAbs to Participate at Upcoming Investor Conferences in September
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company will participate at the following upcoming investor conferences: Thomas Gad, Founder, President and Interim Chief Executive Officer, will participate in a fireside chat at the H.C. Wa
ZacksWall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet
The mean of analysts' price targets for Y-mAbs Therapeutics, Inc. (YMAB) points to an 88.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
